Abstract:Alzheimer's disease (AD) is a growing global healthcare burden affecting the aging population and society. Given the lack of effective treatment to AD, early detection at the prodromal stage and timely monitoring of changes during progression are considered the best approach to control and intervene in disease progression. "Liquid biopsy" of AD biomarkers amyloid-β peptides (Aβs) and tau proteins in the cerebrospinal fluid (CSF) or blood samples holds great promises for cost-effective, widely accessible, and easy-administrated noninvasive detection and follow-up of AD. However, current in vitro detection methods have not yet demonstrated sufficient sensitivity and specificity using neither Aβs nor tau proteins biomarkers. One major challenge of accurate detection and measurement of biomarker levels in biofluidic samples is the biofouling effect with nonspecific adsorption of unwanted biomolecules, such as various serum proteins, on the surface of targeted detecting agents or devices, causing false-positive and false-negative findings. In this study, antibiofouling polymer polyethylene glycol-block-allyl glycidyl ether (PEG-b-AGE) coated magnetic iron oxide nanoparticles (IONPs) capable of suppressing the nonspecific interactions with biomolecules, especially proteins, were investigated for the immunomagnetic capturing of Aβ40 and Aβ42 peptides and tau protein spiked in CSF- and serum-mimicking samples using corresponding antibodies conjugated as targeting ligands. Antibody-conjugated antibiofouling IONPs demonstrated improved specificity (>90%) and sensitivity (>95%) over those of antibody-conjugated magnetic micron beads (Dynabeads, ∼50% specificity and 30-40% sensitivity) widely used as magnetic separating agents under the same experimental conditions with the presence of nontargeted interfering proteins. The antibody-conjugated IONPs also exhibited significantly higher sensitivities (80-90%) and better performance of capturing Aβs and tau protein from the human whole blood samples than antibody-conjugated Dynabeads (∼20%).

Acoustic Aggregation-Induced Separation for Enhanced Fluorescence Detection of Alzheimer's Biomarker.

Fe3O4/MXene Nanosphere-Based Microfluidic Chip for the Accurate Diagnosis of Alzheimer’s Disease

Ultrasound-enhanced Catalytic Hairpin Assembly Capable of Ultrasensitive Microrna Biosensing for the Early Screening of Alzheimer's Disease.

Additive Nanomanufacturing of Lab-on-a-chip Fluorescent Peptide Nanoparticle Arrays for Alzheimer’s Disease Diagnosis

Construction of a microcavity-based microfluidic chip with simultaneous SERS quantification of dual biomarkers for early diagnosis of Alzheimer's disease

Fe 3 O 4 /MXene Nanosphere-Based Microfluidic Chip for the Accurate Diagnosis of Alzheimer’s Disease

Integrated Ultrasonic Aggregation-Induced Enrichment with Raman Enhancement for Ultrasensitive and Rapid Biosensing.

Acoustofluidic multimodal diagnostic system for Alzheimer's disease

Integrating Modification and Detection in Acoustic Microchip for In-Situ Analysis.

Integrated Ultrasound‐Enrichment and Machine Learning in Colorimetric Lateral Flow Assay for Accurate and Sensitive Clinical Alzheimer's Biomarker Diagnosis

Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies (Adv. Sci. 24/2024)

Enrichment of Aggregation-Induced Emission Aggregates Using Acoustic Streaming Tweezers in Microfluidics for Trace Human Serum Albumin Detection.

Paper-based electrochemiluminescence sensor for highly sensitive detection of amyloid-β oligomerization: Toward potential diagnosis of Alzheimer's disease.

Universal Nanoparticle Counting Platform for Tetraplexed Biomarkers by Integrating Immunorecognition and Nucleic Acid Hybridization in One Assay

A Multichannel Fluorescent Tongue for Amyloid-β Aggregates Detection

Extracellular vesicles-based point-of-care testing for the diagnosis and monitoring of Alzheimer's disease

Programmable Microparticle Array for In Situ Modification and Multiple miRNA Detection

In-situ nanozyme catalytic amplification coupled with a universal antibody orientation strategy based electrochemical immunosensor for AD-related biomarker

Extracellular vesicles-based point-of-care testing for the diagnosis and monitoring of Alzheimer’s disease

Improving Sensitivity and Specificity of Amyloid-β Peptides and Tau Protein Detection with Antibiofouling Magnetic Nanoparticles for Liquid Biopsy of Alzheimer's Disease

Entropy-driven Catalysis-Based Lateral Flow Assay for Sensitive Detection of Alzheimer 'S-Associated MicroRNA